Celon Pharma’s pill shows promise in reducing dyskinesia in Parkinson’s trial
HQ Team March 17, 2025: Celon Pharma’s human trial with PDE10A inhibitor, CPL’36, has achieved statistically significant reductions in involuntary movements caused by.
Drugs
Research